- Home
- EXTR vs NVCR Comparison
EXTR vs NVCR Comparison
Compare EXTR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- NVCR
- Stock Information
- Founded
- EXTR 1996
- NVCR 2000
- Country
- EXTR United States
- NVCR Switzerland
- Employees
- EXTR N/A
- NVCR N/A
- Industry
- EXTR Telecommunications Equipment
- NVCR Medical/Dental Instruments
- Sector
- EXTR Telecommunications
- NVCR Health Care
- Exchange
- EXTR Nasdaq
- NVCR Nasdaq
- Market Cap
- EXTR 1.8B
- NVCR 1.9B
- IPO Year
- EXTR 1999
- NVCR 2015
- Fundamental
- Price
- EXTR $14.82
- NVCR $17.44
- Analyst Decision
- EXTR Strong Buy
- NVCR Buy
- Analyst Count
- EXTR 7
- NVCR 6
- Target Price
- EXTR $18.29
- NVCR $32.83
- AVG Volume (30 Days)
- EXTR 1.6M
- NVCR 861.0K
- Earning Date
- EXTR 04-30-2025
- NVCR 04-24-2025
- Dividend Yield
- EXTR N/A
- NVCR N/A
- EPS Growth
- EXTR N/A
- NVCR N/A
- EPS
- EXTR N/A
- NVCR N/A
- Revenue
- EXTR $1,089,717,000.00
- NVCR $621,711,000.00
- Revenue This Year
- EXTR $3.03
- NVCR $2.90
- Revenue Next Year
- EXTR $8.34
- NVCR $10.47
- P/E Ratio
- EXTR N/A
- NVCR N/A
- Revenue Growth
- EXTR N/A
- NVCR 18.27
- 52 Week Low
- EXTR $10.10
- NVCR $14.17
- 52 Week High
- EXTR $19.24
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- EXTR 68.18
- NVCR 48.61
- Support Level
- EXTR $13.64
- NVCR $16.19
- Resistance Level
- EXTR $14.10
- NVCR $18.52
- Average True Range (ATR)
- EXTR 0.51
- NVCR 0.85
- MACD
- EXTR 0.37
- NVCR 0.06
- Stochastic Oscillator
- EXTR 94.74
- NVCR 54.82
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.